Compare Kimberly Clark Corp (KMB) vs Organon & Co. Common Stock (OGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kimberly Clark Corp vs Organon & Co. Common Stock — how do they compare? Kimberly Clark Corp trades at $100 (market cap $32.69B), while Organon & Co. Common Stock trades at $13.58 (market cap $3.62B). The key difference: Kimberly Clark Corp is far larger — about 9× Organon & Co. Common Stock's market cap, and Kimberly Clark Corp pays the higher dividend (5.21%). Which is the better fit depends on your goals — on Pluang, investors hold Kimberly Clark Corp for 94 Days and Organon & Co. Common Stock for 0 Days on average.
| KMB | OGN | |
|---|---|---|
Market Cap | $32.69B | $3.62B |
Volume | 6,331,515 | 2,892,999 |
Sector | Consumer Staples | Health |
52-Week High | $121.44 | $13.81 |
52-Week Low | $93.05 | $5.70 |
Typical Hold Time | 94 Days | 0 Days |
Enterprise Value | $38.25B | $11.04B |
Dividend Yield | 5.21% | 0.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Kimberly-Clark (KMB) trades at $99.41, up 0.65% on the day, showing modest recovery after recent declines. The stock faces technical headwinds with bearish moving averages and overbought RSI signals, while fundamentals reveal mixed results with Q2 2026 earnings miss but strong profitability margins. Recent executive transitions and the pending Kenvue acquisition dominate news flow, creating uncertainty around the company's strategic direction and cash flow sustainability.
KMB presents a complex investment case with a 5.16% dividend yield and 54-year dividend growth streak offset by acquisition risks and cash flow concerns. Analyst consensus at $117.25 suggests 18% upside potential, but the stock requires careful monitoring of integration execution and dividend coverage metrics amid changing leadership.
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Kimberly Clark Corp
With around half of sales from personal care and another third from tissue products, Kimberly-Clark sits as a leading manufacturer of tissue and hygiene realm. Its brand mix includes Huggies, Pull-Ups, Kotex, Depend, Kleenex, and Cottonelle. The firm also operates K-C Professional, which partners with businesses to provide safety and sanitary products for the workplace. Kimberly-Clark generates just over of half its sales in North America and more than 10% in Europe, with the rest primarily concentrated in Asia and Latin America.
Read more on KMB →About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →
